JP2025118607A5 - - Google Patents
Info
- Publication number
- JP2025118607A5 JP2025118607A5 JP2025060888A JP2025060888A JP2025118607A5 JP 2025118607 A5 JP2025118607 A5 JP 2025118607A5 JP 2025060888 A JP2025060888 A JP 2025060888A JP 2025060888 A JP2025060888 A JP 2025060888A JP 2025118607 A5 JP2025118607 A5 JP 2025118607A5
- Authority
- JP
- Japan
- Prior art keywords
- release formulation
- sustained release
- polypeptide
- sustained
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837978P | 2019-04-24 | 2019-04-24 | |
| US62/837,978 | 2019-04-24 | ||
| US201962947188P | 2019-12-12 | 2019-12-12 | |
| US201962947183P | 2019-12-12 | 2019-12-12 | |
| US62/947,183 | 2019-12-12 | ||
| US62/947,188 | 2019-12-12 | ||
| JP2021562971A JP7726791B2 (ja) | 2019-04-24 | 2020-04-24 | 補体活性を調節するための組成物及び方法 |
| PCT/US2020/029733 WO2020219822A1 (en) | 2019-04-24 | 2020-04-24 | Compositions and methods for modulating complement activity |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562971A Division JP7726791B2 (ja) | 2019-04-24 | 2020-04-24 | 補体活性を調節するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025118607A JP2025118607A (ja) | 2025-08-13 |
| JP2025118607A5 true JP2025118607A5 (enExample) | 2025-11-11 |
Family
ID=70977557
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562971A Active JP7726791B2 (ja) | 2019-04-24 | 2020-04-24 | 補体活性を調節するための組成物及び方法 |
| JP2025060888A Pending JP2025118607A (ja) | 2019-04-24 | 2025-04-02 | 補体活性を調節するための組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562971A Active JP7726791B2 (ja) | 2019-04-24 | 2020-04-24 | 補体活性を調節するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220211799A1 (enExample) |
| EP (1) | EP3958842A1 (enExample) |
| JP (2) | JP7726791B2 (enExample) |
| KR (1) | KR20220004039A (enExample) |
| CN (1) | CN113710230A (enExample) |
| AU (1) | AU2020261059A1 (enExample) |
| BR (1) | BR112021017820A2 (enExample) |
| CA (1) | CA3137895A1 (enExample) |
| IL (1) | IL287079A (enExample) |
| MX (1) | MX2021013010A (enExample) |
| SG (1) | SG11202109837SA (enExample) |
| TW (1) | TW202106290A (enExample) |
| WO (1) | WO2020219822A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3154561T3 (pl) | 2014-06-12 | 2019-12-31 | Ra Pharmaceuticals, Inc. | Modulowanie aktywności dopełniacza |
| HRP20211824T1 (hr) | 2015-01-28 | 2022-03-04 | Ra Pharmaceuticals, Inc. | Modulatori aktivnosti komplementa |
| RS60134B1 (sr) | 2015-12-16 | 2020-05-29 | Ra Pharmaceuticals Inc | Modulatori aktivnosti komplementa |
| BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
| EP3870221A1 (en) * | 2018-10-22 | 2021-09-01 | RA Pharmaceuticals, Inc. | Neurological disease treatment with zilucoplan |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1241139A (zh) * | 1996-12-20 | 2000-01-12 | 武田药品工业株式会社 | 生产缓释制剂的方法 |
| WO2000021559A2 (en) | 1998-10-09 | 2000-04-20 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
| CN1787741B (zh) | 2003-05-15 | 2011-08-17 | 唐纳士公司 | 用于预防和治疗败血症的方法与组合物 |
| CN1289066C (zh) * | 2003-09-18 | 2006-12-13 | 中国人民解放军第二军医大学 | 胰高血糖素样肽－1缓释微球制剂及其用途 |
| EP1874289A2 (en) | 2005-03-29 | 2008-01-09 | Cardax Pharmaceuticals, Inc. | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
| JP5707024B2 (ja) | 2005-05-26 | 2015-04-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤 |
| AU2006341116C1 (en) * | 2005-09-27 | 2013-05-23 | Efrat Biopolymers Ltd. | Gelling hydrophobic injectable polymer compositions |
| KR20180002911A (ko) | 2005-11-04 | 2018-01-08 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
| US20090105341A1 (en) * | 2005-12-24 | 2009-04-23 | Teagasc Dairy Products Research Centre | Process for the production of trans-10, cis 12 octadecadienoic acid |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| CA3154415A1 (en) | 2006-10-10 | 2008-04-17 | Regenesance B.V. | Anti-sense oligonucleotide for use in facilitating axonal regeneration |
| US7736860B2 (en) | 2006-11-09 | 2010-06-15 | Univeristy Of Massachusetts | Methods of identifying compounds for the treatment of sterile inflammation |
| US20100015139A1 (en) | 2008-07-10 | 2010-01-21 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF |
| US20080269318A1 (en) | 2007-04-30 | 2008-10-30 | Carmelo Romano | Treatment of age-related macular degeneration using inhibitors of complement factor d |
| JP5683265B2 (ja) | 2007-06-07 | 2015-03-11 | ジェネンテック， インコーポレイテッド | 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法 |
| WO2009014633A1 (en) | 2007-07-20 | 2009-01-29 | Trustees Of The University Of Pennsylvania | Method of treating acute respiratory distress syndrome |
| WO2009053315A1 (en) * | 2007-10-27 | 2009-04-30 | F. Hoffmann-La Roche Ag | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
| EP2331561A4 (en) | 2008-09-03 | 2013-02-27 | Xenome Ltd | PEPTIDE CONJUGATE LIBRARIES AND METHODS OF MAKING SAME |
| US20100086596A1 (en) * | 2008-10-06 | 2010-04-08 | Oakwood Laboratories LLC | Microspheres for releasing an octreotide compound without an initial time lag |
| CN109045296A (zh) | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | 用于治疗补体相关障碍的方法和组合物 |
| DK2488203T3 (en) | 2009-10-16 | 2017-03-13 | Omeros Corp | METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| US9358266B2 (en) | 2010-02-25 | 2016-06-07 | The Trustees Of The University Of Pennsylvania | Treatment of sepsis using complement inhibitors |
| EP2563359A1 (en) | 2010-04-30 | 2013-03-06 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| KR20220044616A (ko) | 2011-04-08 | 2022-04-08 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| WO2012162215A1 (en) | 2011-05-20 | 2012-11-29 | The Trustees Of The University Of Pennsylvania | Promotion of fracture healing using complement inhibitors |
| WO2012174055A1 (en) | 2011-06-13 | 2012-12-20 | The Trustees Of The University Of Pennsylvania | Wound healing using complement inhibitors |
| US20130246083A1 (en) | 2012-03-16 | 2013-09-19 | Alexion Pharmaceuticals, Inc. | Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor |
| US9579360B2 (en) | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| WO2014004733A1 (en) | 2012-06-26 | 2014-01-03 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
| WO2014078622A1 (en) | 2012-11-15 | 2014-05-22 | The Brigham And Women's Hospital, Inc. | Method and system for diagnosing and treating preeclampsia |
| US20140234275A1 (en) | 2013-02-15 | 2014-08-21 | Jason Williams | Method for treating als via the increased production of factor h |
| US20160324798A1 (en) * | 2013-12-31 | 2016-11-10 | Heron Therapeutics, Inc. | Polymer-based compositions for extended release of proteins |
| PL3154561T3 (pl) * | 2014-06-12 | 2019-12-31 | Ra Pharmaceuticals, Inc. | Modulowanie aktywności dopełniacza |
| EP3262410B1 (en) | 2015-02-27 | 2024-08-14 | The Johns Hopkins University | Assay to diagnose and treat disorders of the alternative pathway of complement activation |
| RS60134B1 (sr) * | 2015-12-16 | 2020-05-29 | Ra Pharmaceuticals Inc | Modulatori aktivnosti komplementa |
| BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
| KR20190138806A (ko) * | 2017-04-03 | 2019-12-16 | 인플라알엑스 게엠베하 | C5a 활성 억제제에 의한 염증 질병의 치료 |
-
2020
- 2020-04-24 SG SG11202109837S patent/SG11202109837SA/en unknown
- 2020-04-24 US US17/605,495 patent/US20220211799A1/en active Pending
- 2020-04-24 BR BR112021017820A patent/BR112021017820A2/pt not_active Application Discontinuation
- 2020-04-24 KR KR1020217034548A patent/KR20220004039A/ko not_active Withdrawn
- 2020-04-24 AU AU2020261059A patent/AU2020261059A1/en not_active Abandoned
- 2020-04-24 CN CN202080030772.3A patent/CN113710230A/zh active Pending
- 2020-04-24 MX MX2021013010A patent/MX2021013010A/es unknown
- 2020-04-24 TW TW109113822A patent/TW202106290A/zh unknown
- 2020-04-24 JP JP2021562971A patent/JP7726791B2/ja active Active
- 2020-04-24 CA CA3137895A patent/CA3137895A1/en active Pending
- 2020-04-24 WO PCT/US2020/029733 patent/WO2020219822A1/en not_active Ceased
- 2020-04-24 EP EP20730497.3A patent/EP3958842A1/en active Pending
-
2021
- 2021-10-07 IL IL287079A patent/IL287079A/en unknown
-
2025
- 2025-04-02 JP JP2025060888A patent/JP2025118607A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025118607A5 (enExample) | ||
| TWI241911B (en) | Sustained release ranolazine formulations | |
| JP2637981B2 (ja) | 吸収制御薬剤組成物 | |
| KR102662530B1 (ko) | 양극성 용매에서 안정한 치료 제형들의 제조방법. | |
| WO2006105501A2 (en) | Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin | |
| CZ234898A3 (cs) | Zdokonalené koncentrované injekční a infusní roztoky pro intravazální použití | |
| MX2008016254A (es) | Uso de agonistas del receptor de adenosina a2a en el tratamiento de isquemia. | |
| CA2686094A1 (en) | Manufacturing method of a semiconductor element | |
| JP2017534604A5 (enExample) | ||
| JP5013871B2 (ja) | 経口徐放性医薬組成物 | |
| KR20130126253A (ko) | 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법 | |
| Galanello | Iron chelation: new therapies | |
| CN102580056B (zh) | 一种含抗利尿成分的缓释注射剂及其制备方法 | |
| CN1969814B (zh) | 褪黑素鼻腔给药制剂 | |
| WO2022046976A1 (en) | An epinephrine injection formulation with very low epinephrine concentration and low impurities during its shelf-life | |
| US20170312297A1 (en) | Long Acting Pharmaceutical Compositions For Hepatitis C | |
| JP7518149B2 (ja) | 高濃度インスリン製剤 | |
| JPWO2020219822A5 (enExample) | ||
| EP1364650A1 (en) | Medicinal composition | |
| CA2685214A1 (en) | Improved controlled release oral dosage form | |
| RU2678324C2 (ru) | Составы лоразепама с замедленным высвобождением | |
| RU2471478C1 (ru) | Фармацевтическая композиция для лечения алкоголизма, наркомании и токсикомании с улучшенным профилем высвобождения налтрексона | |
| EP2409701B1 (en) | Prasugrel granules with improved stability | |
| JPH03505447A (ja) | アミオダロンと、ニトロ誘導体、特にイソソルビト二硝酸と、必要に応じてさらにβ―遮断薬とを含む心臓保護効果のある医薬組成物 | |
| KR100605235B1 (ko) | 판토프라졸 함유 경질 캡슐 제제 및 그 제조방법 |